Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
e-SPACE CRM 2026
Author(s): Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira Start date: Apr 11, 2026

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
e-SPACE CRM 2026
Author(s): Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira Start date: Apr 10, 2026

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D
Author(s): Steven E Nissen Added: 2 months ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and… View more

Cardiovascular Kidney Metabolic

Heart Failure
 Ep 146: The Heart Function Revolution: Why Prevention Matters
Added: 7 months ago
In the latest episode of Parallax, Dr Ankur Kalra welcomes Dr Martha Gulati and Dr Anu Lala for a groundbreaking conversation about reimagining heart failure prevention across the entire disease spectrum. Their discussion centres on an innovative scientific statement developed collaboratively between the American Society of Preventive Cardiology and the Heart Failure Society of America - a… View more

Prevention & Chronic Conditions

Heart Failure
Late-Breaking Trail and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions 2025
Added: 1 year ago Source:  ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09… View more

Vascular Disease and Surgery

Heart Failure
e-SPACE Cardio-Renal-Metabolic 2025 – Day Two
Author(s): Nisha Bansal, Antonio Ceriello, David Wheeler ,et al Start date: Apr 05, 2025

Heart Failure

Prevention & Chronic Conditions
e-SPACE Cardio-Renal-Metabolic 2025 – Day One
Author(s): Nisha Bansal, Antonio Ceriello, David Wheeler ,et al Start date: Apr 04, 2025

Heart Failure

Prevention & Chronic Conditions
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF
Author(s): Barry Borlaug Added: 8 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT… View more

Cardiovascular Kidney Metabolic

Heart Failure
HFSA 2025 Late-Breaking Science Collection
Author(s): Nir Uriel Added: 8 months ago
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Society of America's annual congress, HFSA 2025.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators. View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 7 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure